ArticleBioorganic & medicinal chemistry letters2015
Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.
Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed.
- Discovery of a 4'-Azido Fleximer Nucleoside Analog With Broad-Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses.ChemMedChem · 2026Article
- Exploration of 4'-fluoro fleximer nucleoside analogues as potential broad-spectrum antiviral agents.Bioorganic & medicinal chemistry · 2025Article
- Advancements in the development of antivirals against SARS-Coronavirus.Frontiers in cellular and infection microbiology · 2025Review
- Proximal fleximer analogues of 2'-deoxy-2'-fluoro-2'-methyl purine nucleos(t)ides: Synthesis and preliminary pharmacokinetic and antiviral evaluation.Bioorganic & medicinal chemistry · 2024Article
- SARS-CoV-2-induced phosphorylation and its pharmacotherapy backed by artificial intelligence and machine learning.Future science OA · 2024Article
- Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review.Clinical case reports · 2023Article
- Molecular mechanisms of human coronavirus NL63 infection and replication.Virus research · 2023Review
- Design and Synthesis of New Modified Flexible Purine Bases as Potential Inhibitors of Human PNP.Molecules (Basel, Switzerland) · 2023Article
- Synthesis of esters and amides of 2-aryl-1-hydroxy-4-methyl-1H-imidazole-5-carboxylic acids and study of their antiviral activity against orthopoxviruses.Bioorganic & medicinal chemistry letters · 2023Article
- Nucleoside Analogs and Perylene Derivatives Modulate Phase Separation of SARS-CoV-2 N Protein and Genomic RNA In Vitro.International journal of molecular sciences · 2022Article
- Regioselective Synthesis and Molecular Docking Studies of 1,5-Disubstituted 1,2,3-Triazole Derivatives of Pyrimidine Nucleobases.Molecules (Basel, Switzerland) · 2022Article
- 'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.Infectious disorders drug targets · 2022Article
- New Analogues of Uridine as Possible Anti-Viral Agents Specific to SARS-CoV-2.Molecular biology · 2022Article
- Synthesis of New 5'-Norcarbocyclic Aza/Deaza Purine Fleximers - Noncompetitive Inhibitors ofFrontiers in chemistry · 2022Article
- Current Trends and Limitations in Dengue Antiviral Research.Tropical medicine and infectious disease · 2021Review
- A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.International journal of biological macromolecules · 2021Review
- Therapeutic approaches to coronavirus infection according to "One Health" concept.Research in veterinary science · 2021Review
- Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Human coronaviruses and therapeutic drug discovery.Infectious diseases of poverty · 2021Review
- Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2.Transboundary and emerging diseases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A series of doubly flexible nucleoside analogues were designed based on the acyclic sugar scaffold of acyclovir and the flex-base moiety found in the fleximers. The target compounds were evaluated for their antiviral potential and found to inhibit several coronaviruses. Significantly, compound 2 displayed selective antiviral activity (CC50 >3× EC50) towards human coronavirus (HCoV)-NL63 and Middle East respiratory syndrome-coronavirus, but not severe acute respiratory syndrome-coronavirus. In the case of HCoV-NL63 the activity was highly promising with an EC50 <10 μM and a CC50 >100 μM. As such, these doubly flexible nucleoside analogues are viewed as a novel new class of drug candidates with potential for potent inhibition of coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.